Used primarily in pharmaceutical research, this compound is a key intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs), which are designed to degrade specific disease-causing proteins. It incorporates a cereblon (CRBN)-binding moiety linked to a 4-chlorobutanamide chain, enabling conjugation to target protein ligands via nucleophilic substitution. The resulting PROTACs bind effectively to both the target protein and the E3 ubiquitin ligase, facilitating ubiquitination and subsequent degradation. This mechanism is particularly valuable in treating cancers driven by proteins difficult to inhibit with traditional small molecules. Additionally, it is explored for potential in treating neurodegenerative diseases by targeting misfolded proteins.